Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 8/20 | 0.59 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 7/20 | 0.54 |
| ▸ | TP53 | P04637 | 3/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23251483 | 0.88 | MAPT (0.50) | LMNAHSP90AB1MAPTTP53POLB | |
| SCHEMBL23987969 | 0.88 | LMNA (0.60) | LMNAHSP90AB1MAPTTP53POLB | |
| SCHEMBL25064498 | 0.86 | MAPT (0.53) | LMNAHSP90AB1MAPTTP53POLB | |
| SCHEMBL23251521 | 0.84 | MAPT (0.53) | LMNAHSP90AB1MAPTTP53POLB | |
| SCHEMBL24519455 | 0.82 | MAPT (0.50) | LMNAHSP90AB1MAPTTP53HSP90AA1 | |
| SCHEMBL24519454 | 0.82 | MAPT (0.51) | LMNAHSP90AB1MAPTTP53HSP90AA1 | |
| SCHEMBL25689681 | 0.80 | MAPT (0.49) | LMNAHSP90AB1MAPTTP53HSP90AA1 | |
| SCHEMBL23251487 | 0.80 | MAPT (0.49) | LMNAHSP90AB1MAPTTP53HSP90AA1 | |
| SCHEMBL25979956 | 0.80 | MAPT (0.53) | LMNAHSP90AB1MAPTTP53HSP90AA1 | |
| SCHEMBL23251482 | 0.79 | MAPT (0.53) | LMNAHSP90AB1MAPTTP53HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11364300-B2 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | Revolution Medicines, Inc. (US) | 2022-06-21 | — | — | US | disclosed |
| US-20210338824-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210338824-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | MTOR, RICTOR, RPTOR | LMNA 2837/4885HSP90AB1 335/4885MAPT 2872/4885 |
| US-11364300-B2 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | MTOR, RICTOR, RPTOR | LMNA 2837/4885HSP90AB1 335/4885MAPT 2872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.